ENDO: Sweeteners, Genetic Predisposition Independently Linked to Early Puberty
By Elana Gotkine HealthDay Reporter

TUESDAY, July 15, 2025 -- Sweetener consumption and genetic predisposition are independently associated with the risk for central precocious puberty (CPP), according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.
Yang-Ching Chen, M.D., Ph.D., from the Taipei Municipal Wan Fang Hospital in Taiwan, examined sweetener consumption, genetic predisposition, and CPP risk interactions in a population-based cohort of 1,407 children to inform prevention strategies. Validated questionnaires and urinary biomarkers were used to assess sweetener intake, and genetic predisposition was quantified using polygenic risk scores derived from 19 CPP-related single nucleotide polymorphisms.
Chen found that 481 participants were diagnosed with CPP. Significant associations were seen for aspartame, sucralose, glycyrrhizin, and added sugars with an increased risk for CPP, especially in genetically predisposed individuals. There was a dose-dependent relationship noted, with CPP risk amplified by higher intake of these sweeteners. In boys, sucralose showed a stronger association with CPP, while glycyrrhizin, sucralose, and added sugars were especially impactful in girls. There were no significant interaction effects noted between genetic predisposition and sweetener intake.
"The findings are directly relevant to families, pediatricians, and public health authorities," Chen said in a statement. "They suggest that screening for genetic risk and moderating sweetener intake could help prevent early puberty and its long-term health consequences."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-16 06:00
Read more

- Sobi Announces U.S. Food and Drug Administration Approves Doptelet (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
- Are Some 'Low-Grade' Prostate Cancers More Deadly Than Thought?
- COVID Vaccines Saved More Than 2.5 Million Lives, Mostly Seniors
- Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
- Almost 15 Percent of U.S. Seniors Use Aspirin for Primary Prevention
- FDA Approves Empaveli for Rare Kidney Diseases
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions